GEOVAX LABS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
GEOVAX LABS, INC. (GOVX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.18 per share for the 6-month period ending 2026-06-30, per its S-1 filed 2026-09-17.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-09-17
- GEOVAX LABS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $2.48.
- GEOVAX LABS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2015-03-31 was $0.15.
- GEOVAX LABS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2013-03-31 was $0.00.
- GEOVAX LABS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $2.23.
- GEOVAX LABS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- GEOVAX LABS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $0.76, a 80.10% decline from fiscal 2021.
- GEOVAX LABS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $3.82, a 36.92% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.18 S-1 · filed 2026-09-17 | |||
| 2025-12-31 | $62.00 S-1 · filed 2026-09-17 | |||
| 2025-09-30 | $2.48 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $2.48 10-Q · filed 2025-07-28 | |||
| 2025-03-31 | $2.48 10-Q · filed 2025-05-01 | |||
| 2024-12-31 | $2.23 10-K · filed 2025-03-27 | |||
| 2023-12-31 | $0.00 10-K · filed 2024-02-29 | |||
| 2022-12-31 | $0.76 10-K · filed 2023-03-23 | |||
| 2021-12-31 | $3.82 10-K · filed 2022-03-09 | |||
| 2020-12-31 | $2.79 10-K · filed 2021-03-23 | |||
| 2018-12-31 | $0.03 10-K · filed 2019-03-26 | |||
| 2018-09-30 | $0.03 10-Q · filed 2018-11-08 | |||
| 2017-12-31 | $0.05 10-K · filed 2018-03-23 | |||
| 2016-12-31 | $0.07 10-K · filed 2017-03-24 | |||
| 2015-12-31 | $0.11 10-K · filed 2016-03-16 | |||
| 2015-09-30 | $0.15 10-Q · filed 2015-11-12 | |||
| 2015-06-30 | $0.15 10-Q · filed 2015-08-04 | |||
| 2015-03-31 | $0.15 10-Q · filed 2015-05-14 | |||
| 2014-12-31 | $0.17 10-K · filed 2015-03-20 | |||
| 2014-09-30 | $0.29 10-Q · filed 2014-11-12 | |||
| 2014-06-30 | $0.29 10-Q · filed 2014-08-08 | |||
| 2013-12-31 | $0.52 10-K · filed 2014-03-14 | |||
| 2013-09-30 | $0.00 10-Q · filed 2013-11-12 | |||
| 2013-06-30 | $0.00 10-Q · filed 2013-08-12 | |||
| 2013-03-31 | $0.00 10-Q · filed 2013-05-01 | |||
| 2012-12-31 | $0.70 10-K · filed 2013-03-18 | |||
| 2012-09-30 | $0.93 10-Q · filed 2012-11-13 | |||
| 2012-06-30 | $0.94 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B |